Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 30 results found. Search for [ treatment of moderate Covid 19 infections ]

Results 1 to 21 of 30
PTI
June 1, 2021
Saraswat, who was associated in the development of an anti-COVID drug by DRDO, also made it clear that the drug does not have anything to do with Patanjali Ayurved,


BusinessToday.In
May 6, 2021
The approval was granted by the Central Drugs Standards Control Organisation (CDSCO) basis data filed with the US regulators as well as the scientific opinion of an European regulatory panel


BusinessToday.In
April 30, 2021
The Principal Scientific Adviser has advised people to not panic if they experience any COVID-19 symptoms as the majority of people can manage their infections at home by following a few self-care measures


BusinessToday.In
April 23, 2021
Zydus Cadila stated that 91.15 per cent of patients who were treated with the antiviral Virafin were RT-PCR negative by Day 7. The treatment also reduces hours of supplemental oxygen in patients


BusinessToday.In
April 5, 2021
Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients


PTI
February 22, 2021
The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support


BusinessToday.In
January 27, 2021
The American biotech company said its two-antibody cocktail, REGEN-COV, caused a 100% reduction in symptomatic infection and roughly 50% lower overall rates of infection


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research


BusinessToday.In
November 19, 2020
Convalescent Plasma Therapy (CPT) or passive immunotherapy has been tried in the past for treatment of viral infections like H1N1, Ebola and SARS-CoV-1 etc


BusinessToday.In
November 19, 2020
India Stock Market Highlights Today: Infosys, HCL Tech, SBI, Airtel, HUL were among the top losers today, while Bajaj twins, Tata Steel, Titan, ONGC, M&M, NTPC were among the top gainers on Sensex pack 


BusinessToday.In
November 13, 2020
Dalal Street today: IndusInd Bank, followed by SBI, L&T, Axis Bank, HDFC twins, Kotak Bank and ICICI Bank were among the top losers today. On the other hand, Asian Paints, Reliance Industries, Titan, Bajaj Finance and Sun Pharma were trading with gains


Reuters
November 11, 2020
The Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly & Co's bamlanivimab based on trial data


BusinessToday.In
August 18, 2020
\"I have added to the Covid count by testing positive. Mild symptoms n I hope it stays that way,\" Kiran Mazumdar Shaw said in a tweet


Reuters
July 29, 2020
Drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19 and will be available at drug stores from Wednesday, says Hetero


BusinessToday.In
July 14, 2020
Stock Market Highlights on July 14: IndusInd Bank, Bajaj Finserv, Axis Bank, Bajaj Finance, Maruti and SBI were among the other laggards. On the other hand, HCL Tech, Infosys, Nestle India, UltraTech Cement and ITC were the gainers.


BusinessToday.In
July 4, 2020
The drug has been making headlines with many health experts across the world recommending it for treatment of COVID-19. Remdesivir was originally used to treat Ebola patients


PTI
July 1, 2020
Fujifilm is conducting a clinical study on Avigan to treat COVID-19 patients in Japan and the United States and has been seeking to increase the drug's production by partnering with domestic and overseas companies


BusinessToday.In
New Delhi, June 28, 2020
While the general opinion of most experts and pharmaceutical companies is that a corona vaccine would be ready by mid-2021, researchers are still hoping for a 2020 breakthrough


BusinessToday.In
New Delhi, June 20, 2020
Company says Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19; can offer a rapid reduction in viral load in four days and provide faster symptomatic and radiological improvement


Reuters
June 19, 2020
Glenmark said the approval was part of India's accelerated approval process and the drug was meant for 'restricted emergency use,' meaning patients must sign their consent before being treated by the drug


PAGES 1 OF 2  12